An 8-week, Open-Label Clinical Trial of the Efficacy and Safety of Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease
Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 24 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 18 Apr 2016 Status changed from not yet recruiting to recruiting.
- 04 Feb 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.